Compositions and Methods
First Claim
1. A method of treating or reducing a severity of at least one symptom of a gastrointestinal disease associated with a dysbiosis or preventing onset of a dysbiosis, the method comprisingadministering to a human subject a composition consisting essentially of a purified population of germinable bacterial spores in an amount effective to populate at least one region of a gastrointestinal tract in the subject and augment growth of at least one type of bacteria not detectably present in the composition or in the gastrointestinal tract prior to administration to the subject,wherein the composition comprises at least 1×
- 104 colony forming units of germinable bacterial spores per dose of the composition,and the germinable bacterial spores comprise at least two different bacterial entities, each bacterial entity comprising a 16S rDNA at least 97% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, and SEQ ID NO. 1670,thereby treating the gastrointestinal disease or reduce a severity of at least one symptom of the gastrointestinal disease or preventing onset of dysbiosis in the subject.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
-
Citations
30 Claims
-
1. A method of treating or reducing a severity of at least one symptom of a gastrointestinal disease associated with a dysbiosis or preventing onset of a dysbiosis, the method comprising
administering to a human subject a composition consisting essentially of a purified population of germinable bacterial spores in an amount effective to populate at least one region of a gastrointestinal tract in the subject and augment growth of at least one type of bacteria not detectably present in the composition or in the gastrointestinal tract prior to administration to the subject, wherein the composition comprises at least 1× - 104 colony forming units of germinable bacterial spores per dose of the composition,
and the germinable bacterial spores comprise at least two different bacterial entities, each bacterial entity comprising a 16S rDNA at least 97% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO. 673, SEQ ID NO. 674, SEQ ID NO. 774, SEQ ID NO. 845, SEQ ID NO. 847, SEQ ID NO. 848, SEQ ID NO. 856, and SEQ ID NO. 1670, thereby treating the gastrointestinal disease or reduce a severity of at least one symptom of the gastrointestinal disease or preventing onset of dysbiosis in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- 104 colony forming units of germinable bacterial spores per dose of the composition,
Specification